AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer

AbbVie (ABBV) Tops Q1 EPS by 1c; Updates FY16 EPS Outlook

April 28, 2016 7:23 AM EDT

AbbVie (NYSE: ABBV) reported Q1 EPS of $1.15, $0.01 better than the analyst estimate of $1.14. Revenue for the quarter came in at $5.96 billion versus the consensus estimate of $6.03 billion.

GUIDANCE:

AbbVie sees FY2016 EPS of $4.62-$4.82, versus the consensus of $4.97.

The company's 2016 adjusted... More